JOANNA JANKOWSKY to Alzheimer Disease
This is a "connection" page, showing publications JOANNA JANKOWSKY has written about Alzheimer Disease.
Connection Strength
4.342
-
Activity disruption causes degeneration of entorhinal neurons in a mouse model of Alzheimer's circuit dysfunction. Elife. 2022 12 05; 11.
Score: 0.456
-
Gene therapy using A? variants for amyloid reduction. Mol Ther. 2021 07 07; 29(7):2294-2307.
Score: 0.403
-
Cross-species genetic screens to identify kinase targets for APP reduction in Alzheimer's disease. Hum Mol Genet. 2019 06 15; 28(12):2014-2029.
Score: 0.358
-
Combination anti-A? treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice. J Exp Med. 2018 05 07; 215(5):1349-1364.
Score: 0.330
-
Practical considerations for choosing a mouse model of Alzheimer's disease. Mol Neurodegener. 2017 12 22; 12(1):89.
Score: 0.323
-
Discrete Pools of Oligomeric Amyloid-? Track with Spatial Learning Deficits in a Mouse Model of Alzheimer Amyloidosis. Am J Pathol. 2018 03; 188(3):739-756.
Score: 0.323
-
Genetic suppression of transgenic APP rescues Hypersynchronous network activity in a mouse model of Alzeimer's disease. J Neurosci. 2014 Mar 12; 34(11):3826-40.
Score: 0.249
-
Robust amyloid clearance in a mouse model of Alzheimer's disease provides novel insights into the mechanism of amyloid-beta immunotherapy. J Neurosci. 2011 Mar 16; 31(11):4124-36.
Score: 0.202
-
Remote sites of structural atrophy predict later amyloid formation in a mouse model of Alzheimer's disease. Neuroimage. 2010 Apr 01; 50(2):416-27.
Score: 0.186
-
Alzheimer's-type amyloidosis in transgenic mice impairs survival of newborn neurons derived from adult hippocampal neurogenesis. J Neurosci. 2007 Jun 20; 27(25):6771-80.
Score: 0.156
-
Astrocytic Sox9 overexpression in Alzheimer's disease mouse models promotes A? plaque phagocytosis and preserves cognitive function. Nat Neurosci. 2026 Jan; 29(1):88-99.
Score: 0.140
-
Persistent amyloidosis following suppression of Abeta production in a transgenic model of Alzheimer disease. PLoS Med. 2005 Dec; 2(12):e355.
Score: 0.140
-
Environmental enrichment mitigates cognitive deficits in a mouse model of Alzheimer's disease. J Neurosci. 2005 May 25; 25(21):5217-24.
Score: 0.135
-
APP processing and amyloid deposition in mice haplo-insufficient for presenilin 1. Neurobiol Aging. 2004 Aug; 25(7):885-92.
Score: 0.128
-
Environmental enrichment exacerbates amyloid plaque formation in a transgenic mouse model of Alzheimer disease. J Neuropathol Exp Neurol. 2003 Dec; 62(12):1220-7.
Score: 0.122
-
Type I interferon response drives neuroinflammation and synapse loss in Alzheimer disease. J Clin Invest. 2020 04 01; 130(4):1912-1930.
Score: 0.095
-
Combination of A? Suppression and Innate Immune Activation in the Brain Significantly Attenuates Amyloid Plaque Deposition. Am J Pathol. 2017 Dec; 187(12):2886-2894.
Score: 0.079
-
Amyloid-? plaques disrupt axon initial segments. Exp Neurol. 2016 07; 281:93-8.
Score: 0.072
-
Astrocyte-Microglia Cross Talk through Complement Activation Modulates Amyloid Pathology in Mouse Models of Alzheimer's Disease. J Neurosci. 2016 Jan 13; 36(2):577-89.
Score: 0.071
-
Quaternary Structure Defines a Large Class of Amyloid-? Oligomers Neutralized by Sequestration. Cell Rep. 2015 Jun 23; 11(11):1760-71.
Score: 0.068
-
NF?B-activated astroglial release of complement C3 compromises neuronal morphology and function associated with Alzheimer's disease. Neuron. 2015 Jan 07; 85(1):101-115.
Score: 0.066
-
Genetic modulation of soluble A? rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease. J Neurosci. 2014 Jun 04; 34(23):7871-85.
Score: 0.063
-
Impairments in experience-dependent scaling and stability of hippocampal place fields limit spatial learning in a mouse model of Alzheimer's disease. Hippocampus. 2014 Aug; 24(8):963-78.
Score: 0.063
-
Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult. Mol Neurodegener. 2012 Jun 18; 7:28.
Score: 0.055
-
Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum Mol Genet. 2004 Jan 15; 13(2):159-70.
Score: 0.030
-
Transgenic mouse models of neurodegenerative disease: opportunities for therapeutic development. Curr Neurol Neurosci Rep. 2002 Sep; 2(5):457-64.
Score: 0.028